We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sanofi, AstraZeneca Announce Breakthrough Against Leading Cause of Infant Death
Sanofi, AstraZeneca Announce Breakthrough Against Leading Cause of Infant Death
AstraZeneca and Sanofi said an ongoing phase 3 study has shown that their investigational antibody, nirsevimab, can prevent respiratory syncytial virus (RSV) infections in infants.